Cargando…

Is there any difference in the therapeutic effects of Levosimendan on advanced HFrEF patients with sinus rhythm or atrial fibrillation?

Patients with advanced heart failure have a high incidence of atrial fibrillation (AF) and develop into heart failure with reduced ejection fraction (HFrEF), and require higher doses of inotropes. However, it is uncertain about the differences in the effects of levosimendan in HFrEF patients with si...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Wenyan, Li, Fawen, Huang, Huihui, Wu, Xin, Tian, Weixiang, Yu, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995919/
https://www.ncbi.nlm.nih.gov/pubmed/36910542
http://dx.doi.org/10.3389/fcvm.2023.1084300
_version_ 1784902927362555904
author Wang, Wenyan
Li, Fawen
Huang, Huihui
Wu, Xin
Tian, Weixiang
Yu, Tao
author_facet Wang, Wenyan
Li, Fawen
Huang, Huihui
Wu, Xin
Tian, Weixiang
Yu, Tao
author_sort Wang, Wenyan
collection PubMed
description Patients with advanced heart failure have a high incidence of atrial fibrillation (AF) and develop into heart failure with reduced ejection fraction (HFrEF), and require higher doses of inotropes. However, it is uncertain about the differences in the effects of levosimendan in HFrEF patients with sinus rhythm or AF. A total of 63 advanced HFrEF subjects (ejection fraction < 40%) were divided into sinus rhythm (SR, n = 34) and atrial fibrillation (AF, n = 29) cohorts. All patients received six cycles of intermittent repeated levosimendan infusion. After 3 months of treatment, B-type natriuretic peptide (BNP), estimated glomerular filtration rate, resting heart rate (rHR), creatinine, left ventricle ejection fraction (LVEF), left ventricular end diastolic diameter and blood pressure body weight, NYHA classification were measured. After completing the course of treatment, LVEF, BNP, and rHR were significantly decreased (p < 0.0.5), and no significant differences between the two groups were observed (p > 0.05). The NYHA classification improved in the SR group but not in the AF group. There was no significant difference between patients with different rHRs (≤70 bpm vs. >70 bpm) in the SR group (p > 0.05) or in the AF group (rHR ≤ 90 bpm vs. rHR >90 bpm) (p > 0.05). This study showed no difference in the therapeutic effect of intermittent repeated levosimendan infusion on advanced HFrEF with different heart rhythms (SR or AF); Advanced HFrEF patients receive levosimendan treatment without taking the inference of heart rhythm.
format Online
Article
Text
id pubmed-9995919
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99959192023-03-10 Is there any difference in the therapeutic effects of Levosimendan on advanced HFrEF patients with sinus rhythm or atrial fibrillation? Wang, Wenyan Li, Fawen Huang, Huihui Wu, Xin Tian, Weixiang Yu, Tao Front Cardiovasc Med Cardiovascular Medicine Patients with advanced heart failure have a high incidence of atrial fibrillation (AF) and develop into heart failure with reduced ejection fraction (HFrEF), and require higher doses of inotropes. However, it is uncertain about the differences in the effects of levosimendan in HFrEF patients with sinus rhythm or AF. A total of 63 advanced HFrEF subjects (ejection fraction < 40%) were divided into sinus rhythm (SR, n = 34) and atrial fibrillation (AF, n = 29) cohorts. All patients received six cycles of intermittent repeated levosimendan infusion. After 3 months of treatment, B-type natriuretic peptide (BNP), estimated glomerular filtration rate, resting heart rate (rHR), creatinine, left ventricle ejection fraction (LVEF), left ventricular end diastolic diameter and blood pressure body weight, NYHA classification were measured. After completing the course of treatment, LVEF, BNP, and rHR were significantly decreased (p < 0.0.5), and no significant differences between the two groups were observed (p > 0.05). The NYHA classification improved in the SR group but not in the AF group. There was no significant difference between patients with different rHRs (≤70 bpm vs. >70 bpm) in the SR group (p > 0.05) or in the AF group (rHR ≤ 90 bpm vs. rHR >90 bpm) (p > 0.05). This study showed no difference in the therapeutic effect of intermittent repeated levosimendan infusion on advanced HFrEF with different heart rhythms (SR or AF); Advanced HFrEF patients receive levosimendan treatment without taking the inference of heart rhythm. Frontiers Media S.A. 2023-02-23 /pmc/articles/PMC9995919/ /pubmed/36910542 http://dx.doi.org/10.3389/fcvm.2023.1084300 Text en Copyright © 2023 Wang, Li, Huang, Wu, Tian and Yu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Wang, Wenyan
Li, Fawen
Huang, Huihui
Wu, Xin
Tian, Weixiang
Yu, Tao
Is there any difference in the therapeutic effects of Levosimendan on advanced HFrEF patients with sinus rhythm or atrial fibrillation?
title Is there any difference in the therapeutic effects of Levosimendan on advanced HFrEF patients with sinus rhythm or atrial fibrillation?
title_full Is there any difference in the therapeutic effects of Levosimendan on advanced HFrEF patients with sinus rhythm or atrial fibrillation?
title_fullStr Is there any difference in the therapeutic effects of Levosimendan on advanced HFrEF patients with sinus rhythm or atrial fibrillation?
title_full_unstemmed Is there any difference in the therapeutic effects of Levosimendan on advanced HFrEF patients with sinus rhythm or atrial fibrillation?
title_short Is there any difference in the therapeutic effects of Levosimendan on advanced HFrEF patients with sinus rhythm or atrial fibrillation?
title_sort is there any difference in the therapeutic effects of levosimendan on advanced hfref patients with sinus rhythm or atrial fibrillation?
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995919/
https://www.ncbi.nlm.nih.gov/pubmed/36910542
http://dx.doi.org/10.3389/fcvm.2023.1084300
work_keys_str_mv AT wangwenyan isthereanydifferenceinthetherapeuticeffectsoflevosimendanonadvancedhfrefpatientswithsinusrhythmoratrialfibrillation
AT lifawen isthereanydifferenceinthetherapeuticeffectsoflevosimendanonadvancedhfrefpatientswithsinusrhythmoratrialfibrillation
AT huanghuihui isthereanydifferenceinthetherapeuticeffectsoflevosimendanonadvancedhfrefpatientswithsinusrhythmoratrialfibrillation
AT wuxin isthereanydifferenceinthetherapeuticeffectsoflevosimendanonadvancedhfrefpatientswithsinusrhythmoratrialfibrillation
AT tianweixiang isthereanydifferenceinthetherapeuticeffectsoflevosimendanonadvancedhfrefpatientswithsinusrhythmoratrialfibrillation
AT yutao isthereanydifferenceinthetherapeuticeffectsoflevosimendanonadvancedhfrefpatientswithsinusrhythmoratrialfibrillation